Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Glioblastoma Multiforme of Brain: early-phase trial registry
8 of 12 indexed Glioblastoma Multiforme of Brain trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,429 of 28,707 conditions by registered trial count.
12 US clinical trials · 8 currently recruiting · #1,429 of 28,707 conditions by registered trial count
Glioblastoma Multiforme of Brain: 12 US clinical trials tracked, 8 recruiting.
Glioblastoma Multiforme of Brain is the subject of 12 registered US clinical trials on ClinicalTrials.gov, 8 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most active sponsor is Jasper Gerritsen, running 2 of these trials.
Enrollment posture brief
Registry condition glioblastoma-multiforme-of-brain
OPEN 8 | RECR 67% | LATE 0 | EARLY 8 | RANK #1429 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Acute Hypoxemic Respiratory Failure (67% recruiting · 6 trials)
Glioblastoma Multiforme of Brain lists 8 open slots (67% of 12 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Glioblastoma Multiforme of Brain on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Glioblastoma Multiforme of Brain is recruiting above its size-band peers.
8 of 12 indexed trials (66.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Glioblastoma Multiforme of Brain research.
Jasper Gerritsen accounts for 2 of 12 trials (16.7%). 11 distinct sponsors appear on at least one study for this condition label.
-
Typical Glioblastoma Multiforme of Brain enrolment sits around 42 participants.
Median target enrolment is 42 among the 12 trials that report a genuine target (sentinel values excluded). 7 of those (58.3%) plan for fewer than 100 participants.
-
Glioblastoma Multiforme of Brain research is mostly interventional.
9 interventional and 3 observational studies make up this index (75% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
12 total, page 1 of 1
The RESBIOP-study: Resection Versus Biopsy in High-grade Glioma Patients (ENCRAM 2202)
Jasper Gerritsen
NCT06146725
The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302)
Jasper Gerritsen
NCT06283927
The RECMAP-study: Resection With or Without Intraoperative Mapping for Recurrent Glioblastoma
Erasmus Medical Center
NCT06273176
Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma
Baptist Health South Florida
NCT06991101
Intracavitary Photodynamic Therapy as an Adjuvant to Resection of Glioblastoma or Gliosarcoma Using IV Photobac®
Photolitec
NCT05363826
GPC-3 CAR T CELLS FOR Recurrent GPC-3 Positive Glioblastoma
Baylor College of Medicine
NCT06815432
Multitracer [18F]Fluciclovine and 18F-FDG PET, and Advanced MRI for Metabolic Profiling of Glioblastoma
Abramson Cancer Center at Penn Medicine
NCT06613841
Omental Tissue Autograft in Human Recurrent Glioblastoma Multiforme (rGBM)
Northwell Health
NCT05979064
Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM)
TVAX Biomedical
NCT05685004
Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma
Nader Sanai
NCT05076513
CAR T Cells in Patients With MMP2+ Recurrent or Progressive Glioblastoma
Chimeric Therapeutics
NCT05627323
Trial of C134 in Patients With Recurrent GBM
University of Alabama at Birmingham
NCT03657576
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 6 |
| Phase 2 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Glioblastoma Multiforme of Brain records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Glioblastoma Multiforme of Brain trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Glioblastoma Multiforme of Brain page
12 registered trials, 8 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 8 Glioblastoma Multiforme of Brain trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Jasper Gerritsen sponsors the most Glioblastoma Multiforme of Brain trials on record, review their full trial history before evaluating a specific study. See Jasper Gerritsen's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Glioblastoma Multiforme of Brain condition card totals 12 registered trials; most-linked intervention Temozolomide; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.